<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03082833</url>
  </required_header>
  <id_info>
    <org_study_id>2016-08-016</org_study_id>
    <nct_id>NCT03082833</nct_id>
  </id_info>
  <brief_title>Phase II Trial of AZD2014 in TSC1/2 Mutated or TSC1/2 Null GC Patients as Second-line Chemotherapy</brief_title>
  <official_title>Samsung Medical Center</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II trial of AZD2014 in TSC1/2 mutated or TSC1/2 null GC patients as second-line
      chemotherapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AZD2014 50mg BD continuous schedule of a 28 day cycle AZD2014 will be administered with
      orange juice in STG/TG patients. AZD2014 can be taken with or without food. The first dose of
      the day should be taken at approximately the same time each morning.The second dose of the
      day should be taken approximately 12 hours after the morning dose.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR) by RECIST 1.1</measure>
    <time_frame>6 months</time_frame>
    <description>Objective response rate (ORR) by RECIST 1.1</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Cancer of Stomach</condition>
  <arm_group>
    <arm_group_label>AZD2014 50mg BD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD2014 50mg BD continuous schedule of a 28 day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD2014</intervention_name>
    <description>AZD2014 is a selective dual mTOR kinase inhibitor targeting both mTORC1 (rapamycin sensitive) and mTORC2 (rapamycin insensitive) complexes of mammalian Target Of Rapamycin (mTOR).</description>
    <arm_group_label>AZD2014 50mg BD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of fully informed consent prior to any study specific procedures.

          2. Patients must be ≥20 years of age.

          3. Advanced gastric adenocarcinoma (including GEJ) that has progressed during or after
             first-line therapy.

               -  The 1st line regimen must have contained doublet 5-fluoropyrimidine and platinum
                  based regimen.

               -  Relapse within 6 months of completion of adjuvant/neoadjuvant chemotherapy
                  containing doublet 5-fluoropyrimidine and platinum-based regimen could be
                  considered as 1st line therapy.

               -  Acceptable prior chemotherapy regimens for this protocol are chemotherapy
                  regimens that include Immune Target agent therapy. (such as a pembrolizumab,
                  ramucirumab etc)

          4. Previous adjuvant/neoadjuvant chemotherapy is allowed, if completed more than 6 months
             prior to starting the 1st line therapy.

          5. Provision of tumor sample (from eith tumor sample (from eith tumor sample (from eith
             tumor sample (from eith tumor sample (from eith er a resection or biopsy)er a
             resection or biopsy) er a resection or biopsy)er a resection or biopsy) er a resection
             or biopsy)er a resection or biopsy)er a resection or biopsy)er a resection or
             biopsy)er a resection or biopsy) er a resection or biopsy) er a resection or biopsy)
             er a resection or biopsy)er a resection or biopsy)

          6. Patients with TSC1/2 mutation or null through the VIKTORY trial. (The VIKTORY trial
             uses Ion Torrent PGM to screen for a panel of cancer mutations and nanostring copy
             number variation panel (see addendum for the VIKTORY trial). Types of TSC1/2 mutation
             for this trial was defined in VIKTORY lab manual

          7. Patients are willing and able to comply with the protocol for the duration of the
             study including undergoing treatment and scheduled visits and examinations.

          8. ECOG performance status 0-2.

          9. Patients must have a life expectancy ≥ 3 months from proposed first dose date.

         10. Patients must have acceptable bone marrow, liver and renal function measured within 28
             days prior to administration of study treatment as defined below:

             - Haemoglobin ≥9.0 g/dL (transfusion allowed)

               -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/L

               -  White blood cells (WBC) &gt; 3 x 109/L

               -  Platelet count ≥100 x 109/L (transfusion allowed)

               -  Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN)

               -  AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional upper limit of normal unless liver
                  metastases are present in which case it must be ≤ 5x ULN

               -  Serum creatinine ≤1.5 x institutional ULN

         11. At least one measurable lesion that can be accurately assessed by imaging or physical
             examination at baseline and following up visits.

         12. Negative urine or serum pregnancy test within 28 days of study treatment, confirmed
             prior to treatment on day 1. Patients of child-bearing potential should be using
             adequate contraceptive measures (two forms of highly reliable methods) should not be
             breast feeding and must have a negative pregnancy test prior to start of dosing.Or
             Patients must have evidence of non-child-bearing potential by fulfilling one of the
             following criteria at screening: Post-menopausal - defined as aged more than 50 years
             and amenorrhoeic for at least 12 months following cessation of all exogenous hormonal
             treatments. Documentation of irreversible surgical sterilisation by hysterectomy,
             bilateral oophorectomy or bilateral salpingectomy, but not tubal ligation

        Exclusion Criteria:

          -  1. More than one prior chemotherapy regimen (except for adjuvant/neoadjuvant
             chemotherapy with more than 6 month wash out period) for the treatment of gastric
             cancer in the advanced setting.

             2. Any previous treatment with PIK3CA, AKT or mTOR inhibitor or agents with mixed PI3K
             / mTOR activity.

             3. Patients with second primary cancer, except: adequately treated non-melanoma skin
             cancer, curatively treated in-situ cancer of the cervix, or other solid tumours
             curatively treated with no evidence of disease for ≤5 years.

             4. Patients unable to swallow orally administered medication. 5. Previous major
             surgery within 4 weeks prior to enrollment. 6. For AZD2014: Exposure to potent or
             moderate inhibitors or inducers of CYP3A4/5 if taken within the stated washout periods
             before the first dose of study treatment 8. With the exception of alopecia, any
             ongoing toxicities (&gt;CTCAE grade 1) caused by previous cancer therapy.

             9. Intestinal obstruction or CTCAE grade 3 or grade 4 upper GI bleeding within 4 weeks
             before the enrollment.

             10. Resting ECG with measurable QTcB &gt; 450 msec on 2 or more time points within a 24
             hour period or family history of long QT syndrome.

             11. Patients with cardiac problem as follows: uncontrolled hypertension (BP ≥150/95
             mmHg despite medical therapy) Left ventricular ejection fraction &lt;55% measured by
             echocardiography, Atrial fibrillation with a ventricular rate &gt;100 bpm on ECG at rest
             , Symptomatic heart failure (NYHA grade II-IV), Prior or current cardiomyopathy,
             Severe valvular heart disease, Uncontrolled angina (Canadian Cardiovascular Society
             grade II-IV despite medical therapy), Acute coronary syndrome within 6 months prior to
             starting treatment 12. Active or untreated brain metastases or spinal cord compression
             Patients with treated brain metastases or spinal cord compression are eligible if they
             have minimal neurologic symptoms, evidence of stable disease (for at least 1 month) or
             response on follow-up scan, and require no corticosteroid therapy for ≥ 1 week.

             13. Female patients who are breast-feeding or child-bearing 14. Any evidence of severe
             or uncontrolled systemic disease, active infection, active bleeding diatheses or renal
             transplant, including any patient known to have hepatitis B, hepatitis C or human
             immunodeficiency virus (HIV) 15. Patients with proteinuria (3+ on dipstick analysis )
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2017</study_first_submitted>
  <study_first_submitted_qc>March 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2017</study_first_posted>
  <last_update_submitted>March 12, 2017</last_update_submitted>
  <last_update_submitted_qc>March 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Jeeyun Lee</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

